Insulin glargine
A long-acting basal insulin analogue for once-daily use in type 1 and type 2 diabetes.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Insulin glargine
A long-acting basal insulin analogue for once-daily use in type 1 and type 2 diabetes.
Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.
Regulatory statement in source: FDA-approved.
Insulin glargine is a long-acting recombinant human insulin analog engineered to provide a relatively steady, once-daily basal insulin profile. It is approved by the FDA to improve glycemic control in adults and children with type 1 diabetes and in adults with type 2 diabetes, and it is not intended for treating diabetic ketoacidosis. Regulatory review covered pharmacokinetics, cardiovascular outcomes, and immunogenicity across large clinical trial programs.
Benefits reported in the imported source
- Both type 1 and type 2 diabetes, with regulatory review covering large clinical trial programs.
- Long-acting profile allows once-daily basal dosing, reviewed and labeled for use across vial, cartridge, and prefilled-pen presentations.
- Decades of postmarketing surveillance data since its original approval in 2000.
Risks and limits
- Carries a boxed warning against use for treating diabetic ketoacidosis, which requires a different insulin regimen.
- Hypoglycemia, allergic reactions, and injection-site lipodystrophy are labeled adverse reactions.
- Not studied in children under six years of age or in pediatric type 2 diabetes.
Source bottom line: Insulin glargine is an FDA-approved long-acting basal insulin analog for type 1 and type 2 diabetes, with labeling that individualizes dosing rather than specifying a single universal amount.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
adults and children age six and older with type 1 diabetes mellitus; adults with type 2 diabetes mellitus
- Reported regimen
- subcutaneous injection once daily at the same time each day, via vial, cartridge, or prefilled SoloStar pen, at a labeled starting dosage for insulin-naive type 2 patients of 10 units or 0.2 units per kilogram daily, individually titrated thereafter
- Duration
- ongoing daily basal dosing, titrated based on periodic blood glucose monitoring
- Reported outcome
- FDA-approved basal insulin analog shown in labeling trials to improve glycemic control versus comparator insulin regimens
- Source
- LANTUS (insulin glargine) injection label — DailyMed
Claim provenance
evidence.json#/catalog:medication:insulin/protocols/0
adults and pediatric patients with type 1 or type 2 diabetes mellitus
- Reported regimen
- full prescribing information covering dose individualization, injection site rotation, and storage conditions for vial, cartridge, and prefilled pen presentations
- Duration
- chronic, ongoing basal insulin therapy
- Reported outcome
- complete FDA-approved prescribing information including boxed warning against use for treating diabetic ketoacidosis and against insulin pump or intravenous use
- Source
- LANTUS full prescribing information — FDA AccessData (availability check 2026-10-15: response exceeded review limit; not fully inspected; HTTP 200)
Claim provenance
evidence.json#/catalog:medication:insulin/protocols/1
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Historical research outcome: no-verified-description · 2026-10-06
No suitable community description was independently verified in these checks. The entry remains empty; this does not establish that no practice exists elsewhere.
- https://www.nhs.uk/medicines/insulin/insulin-for-type-1-diabetes/: no-practice-description — This retrieved source was checked, but no suitable community description was independently verified. Research regimens, expert advice, product identity and efficacy claims were not repurposed.
- https://www.nhs.uk/medicines/insulin/: no-practice-description — This retrieved source was checked, but no suitable community description was independently verified. Research regimens, expert advice, product identity and efficacy claims were not repurposed.
Pharmacokinetic context
Historical half-life estimate: 12 hours. Bolli et al. 2026, Diabetes Obes Metab, PMID 42046184 — modeled literature estimate, not a figure stated in the FDA label, which describes only a flat 24-hour release profile qualitatively Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.
Source references
- LANTUS (insulin glargine) injection label — DailyMed
- LANTUS full prescribing information — FDA AccessData (availability check 2026-10-15: response exceeded review limit; not fully inspected; HTTP 200)
Snapshot provenance
Source ID: catalog:medication:insulin. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.